Drug profile · INN
sitagliptin hydrochloride
BRYNOVIN
sitagliptin hydrochloride (BRYNOVIN) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Drug details — sitagliptin hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 14
- Data quality
- 0.84
Quick answer
sitagliptin hydrochloride (BRYNOVIN) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is sitagliptin hydrochloride?
sitagliptin hydrochloride (BRYNOVIN) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sitagliptin hydrochloride?
BRYNOVIN is a marketed brand name for sitagliptin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sitagliptin hydrochloride?
sitagliptin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.